^Pertz H, Elz S (April 1995). "In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery". The Journal of Pharmacy and Pharmacology. 47 (4): 310–6.
doi:
10.1111/j.2042-7158.1995.tb05801.x.
PMID7791029.
S2CID25311518.
^Nishio H, Inoue A, Nakata Y (1996). "Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes". Archives Internationales de Pharmacodynamie et de Therapie. 331 (2): 189–202.
PMID8937629.
^Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A (April 1993). "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus". Thrombosis Research. 70 (2): 131–8.
doi:
10.1016/0049-3848(93)90154-g.
PMID8322284.
^Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, et al. (1999). "The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients". Clinical and Experimental Pharmacology & Physiology. 26 (5–6): 461–4.
doi:
10.1111/j.1440-1681.1999.03056.x.
PMID10386239.
S2CID31041268.
^Rydzewski A, Urano T, Hachiya T, Kaneko H, Baba S, Takada Y, Takada A (December 1996). "The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease". Thrombosis Research. 84 (6): 445–52.
doi:
10.1016/s0049-3848(96)00212-5.
PMID8987165.
^Igarashi M, Okuda T, Oh-i T, Koga M (October 2000). "Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist". The Journal of Dermatology. 27 (10): 643–50.
doi:
10.1111/j.1346-8138.2000.tb02246.x.
PMID11092268.
S2CID24884976.
^Kinugawa T, Fujita M, Lee JD, Nakajima H, Hanada H, Miyamoto S (August 2002). "Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris". American Heart Journal. 144 (2): A1–A6.
doi:
10.1067/mhj.2002.124056.
PMID12177659.
^Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Arockia Rani PJ, Kano H, et al. (May 2003). "Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism". Atherosclerosis. 168 (1): 23–31.
doi:
10.1016/s0021-9150(03)00054-6.
PMID12732383.
^Pertz H, Elz S (April 1995). "In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery". The Journal of Pharmacy and Pharmacology. 47 (4): 310–6.
doi:
10.1111/j.2042-7158.1995.tb05801.x.
PMID7791029.
S2CID25311518.
^Nishio H, Inoue A, Nakata Y (1996). "Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes". Archives Internationales de Pharmacodynamie et de Therapie. 331 (2): 189–202.
PMID8937629.
^Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A (April 1993). "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus". Thrombosis Research. 70 (2): 131–8.
doi:
10.1016/0049-3848(93)90154-g.
PMID8322284.
^Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, et al. (1999). "The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients". Clinical and Experimental Pharmacology & Physiology. 26 (5–6): 461–4.
doi:
10.1111/j.1440-1681.1999.03056.x.
PMID10386239.
S2CID31041268.
^Rydzewski A, Urano T, Hachiya T, Kaneko H, Baba S, Takada Y, Takada A (December 1996). "The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease". Thrombosis Research. 84 (6): 445–52.
doi:
10.1016/s0049-3848(96)00212-5.
PMID8987165.
^Igarashi M, Okuda T, Oh-i T, Koga M (October 2000). "Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist". The Journal of Dermatology. 27 (10): 643–50.
doi:
10.1111/j.1346-8138.2000.tb02246.x.
PMID11092268.
S2CID24884976.
^Kinugawa T, Fujita M, Lee JD, Nakajima H, Hanada H, Miyamoto S (August 2002). "Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris". American Heart Journal. 144 (2): A1–A6.
doi:
10.1067/mhj.2002.124056.
PMID12177659.
^Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Arockia Rani PJ, Kano H, et al. (May 2003). "Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism". Atherosclerosis. 168 (1): 23–31.
doi:
10.1016/s0021-9150(03)00054-6.
PMID12732383.